

CURRICULUM VITAE Elham Gholami

Born in April 14th 1979 Tehran, Iran



Nationality: Iranian

Address:

Molecular Immunology and Vaccine Research Laboratory, Dept. of Immunology, Pasteur Institute of Iran, Tehran, Iran 13164

Tel: 0098 21 695 3311-20 Ext. 2112/2115/2110

Fax: 0098 21 695 3311-20 Ext. 2115

E-mail: elham_gholami@yahoo.com

Education:

- BSc. On **Microbiology**, School of sciences, University of Azad, Karaj (1998-2003)
- MSc. On **Molecular cell biology**, University of Khatam (2003-2006) Thesis: Immunologic and protective effects of prime-boost vaccination of *L. major* HSP70 in BALB/c and C57BL/6 mice models under supervision of Dr. Sima Rafati

Total average: 17.69 out of 20

Work experience:

- Sina Medical diagnostic Laboratory in Karaj (1998-2003)
- Workshop in Department of microbiology (1999), Razi Institute of Iran
- Workshop in Department of biotechnology (2001), Razi Institute of Iran
- Workshop Cell Culture in cellular bank of Iran, Pasteur Institute of Iran (2006)
- Working as M.Sc. student on thesis project entitled: "Immunologic and protective effects of prime-boost vaccination of *L. major* HSP70 in BALB/c and C57BL/6 mice models" under Supervision of Dr. Rafati in Molecular Immunology and Vaccine Research Laboratory; Department of Immunology; Pasteur Institute of Iran (2005-2006).
- Working as research assistant in Molecular Immunology and Vaccine Research lab, Department of Immunology, Pasteur Institute of Iran, 2006-present.

PUBLICATIONS

1. Rafati S, **Gholami E**, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L. *Leishmania major* heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. *Vaccine*. **2007** 22; 25 (21):4159-69.

National and International Congress

- 1- 4th world congress on Leishmaniasis 2009, WorldLesh4, 3-7 February **2009**, Luchnow, India. Analysis of survival and growth rate of *Leishmania major* heterozygote mutant of signal peptidase type I. Tahereh Taheri, **Elham Gholami**, Fatemeh Doustdari, Ali-Hatef Salmanian, Sima Rafati.

- 2- The 9th Iranian congress of immunology and allergy, 13-15 Jun **2008** Tehran, Iran. Khoshgoo N, Zahedifard F, **Gholami E**, Rafati S. Evaluation of prime-boost vaccination using Cystein proteinase type III (CPC) of *L infantum* in BALB/c mice
- 3- The 9th Iranian congress of immunology and allergy, 13-15 Jun **2008** Tehran, Iran. Abdian N, **Gholami E**, Zahedifard F, Rafati S. Evaluation of DNA/DNA and Prime-boost Vaccination using LPG3 against *L. major* infection in susceptible BALB/c mice.
- 4- The 1st International Congress on Health Genomics and Biotechnology. 24-26 Nov **2007**, Tehran, Iran. *Leishmana major* heat shock protein 70 (HSP70) stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients but not protective in mice model of experimental cutaneous leishmaniasis. **E. Gholami**, N. Hassani, F. Ghaemimanesh, Y. Taslimi, T. Taheri and S. Rafati
- 5- The 9th Iranian congress of biochemistry and The 2th International congress of biochemistry and biology, 28-31 Oct **2007** Shiraz, Iran. **Gholami E**, Hassani N, Ghaemimanesh F, Rafati S. *Leishmania major* Heat Shock Protein 70 (HSP70) stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients but not protective in murine models of cutaneous leishmaniasis.
- 6- The 4th Iranian Congress of Virology, 30 March-2 April **2007**
- 7- The 8th Iranian congress of immunology and allergy, 14-16 May **2006** Tehran, Iran. **Gholami E**, Hassani N, Ghaemimanesh F, Rafati S. Cloning, expression of *L. major* Heat Shock Protein 70 (*LmHSP70*) and evaluation of its potential protection in the murine models.
- 8- The 8th Iranian congress of immunology and allergy, 14-16 May **2006** Tehran, Iran. Hassani N, **Gholami E**, Ghaemimanesh F, Taslimi Y, Rafati S. The highly evolutionary conserved protein HSP70 is a major target of the humoral immune response during *Leishmania* infections.

Current Project:

1. Evaluation of VP22 of HSV-1 and its efficiency in DNA vaccination by fusing to Amastin of *L. major*. (ID. No. 429)
2. Gene disruption of Type I signal peptidase and evaluation of its role in growth, survival, infectivity and protection in *Leishmania major*. (ID. No. 271)

Professional Research Experience:

- Evaluation of new gene candidate for vaccine development against cutaneous and visceral Leishmaniasis by applying numerous techniques and methods (Pasteur Institute of Iran, since 2006 to present)